SELLAS Life Sciences (SLS) Equity Ratio (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Equity Ratio for 9 consecutive years, with 0.6 as the latest value for Q3 2024.
- Quarterly Equity Ratio rose 226.69% to 0.6 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was 0.6 through Sep 2024, up 226.69% year-over-year, with the annual reading at 1.28 for FY2023, 653.7% down from the prior year.
- Equity Ratio for Q3 2024 was 0.6 at SELLAS Life Sciences, up from 0.19 in the prior quarter.
- The five-year high for Equity Ratio was 0.77 in Q4 2021, with the low at 1.28 in Q4 2023.
- Average Equity Ratio over 5 years is 0.33, with a median of 0.45 recorded in 2023.
- The sharpest move saw Equity Ratio plummeted 653.7% in 2023, then surged 226.69% in 2024.
- Over 5 years, Equity Ratio stood at 0.61 in 2020, then rose by 27.53% to 0.77 in 2021, then plummeted by 70.09% to 0.23 in 2022, then tumbled by 653.7% to 1.28 in 2023, then surged by 146.75% to 0.6 in 2024.
- According to Business Quant data, Equity Ratio over the past three periods came in at 0.6, 0.19, and 0.4 for Q3 2024, Q2 2024, and Q1 2024 respectively.